The abstract is read at the publisher; the summary is JClub's.
Targeted oral kudzu extract in 120 adults with alcohol use disorder who binge drink reduced binge-drinking days versus placebo (ITT IRR=0.73, 95% CI=0.54–0.99).
- Why it matters: Binge drinking is common in adults with AUD, and there is a need for acceptable, targeted pharmacologic options that reduce binge episodes during treatment.
- What they did: In a double-blind, placebo-controlled phase 2b trial, participants received weekly counseling for 12 weeks and took kudzu 2 grams on days binge drinking was anticipated, with primary outcome as binge-drinking days in the past week.
- The result: Kudzu also reduced binge-drinking weeks (ITT RR=0.79, 95% CI=0.62–0.99) and PEth positivity in as-treated analyses (RR=0.82, 95% CI=0.67–0.99), with sustained reductions at 3 months and similar adverse-event frequency.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.